Fig. 2
From: Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2
AAV2MEC1 virus targets EpCAM-positive tumors in vivo. A: Bioluminescence imaging of 4T-1 tumor in mice. The mice were divided into three groups and were respectively injected with AAV2, AAV2M, and AAV2MEC1 vector, with a single dosage of 1 × 10^11 AAV particles per mouse via intravenous injection. On day 7 after injection, the bioluminescence imaging was conducted to detect the expression of luciferin in the mice using an in vivo imaging system. The red circles show the sites of tumor cell injections. B: Ex vivo bioimaging of organs in mice from each group (tumor, heart, liver, spleen, lung, kidney, and muscle). The luminescence signal intensity was expressed as photons/second/square centimeter/steradian (p/sec/cm2/sr). C: Luciferase activity assay indicates targeted delivery of the gene to the tumor. Two weeks after injection, the mice were euthanized, and multiple tissues (liver, heart, lung, kidney, spleen, skeletal muscle, and tumor) were collected for quantitative luciferin measurement. The luciferase activity are reported as relative light units per mg tissue (RLUs/mg tissue). Data are presented as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ns statistically not significant